Background Although use of gonadotropin-releasing hormone agonist (GnRHa) during
chemotherapy is an established strategy to protect ovarian function in premenopausal …

Purpose The role of temporary ovarian suppression with gonadotropin-releasing hormone
agonists (GnRHa) during chemotherapy as a strategy to preserve ovarian function and …

Importance Chemotherapy may result in a detrimental effect on ovarian function and fertility
in premenopausal women undergoing treatment for early-stage breast cancer (EBC). To …

Chemotherapy-induced premature ovarian insufficiency (POI) is one of the potential
drawbacks of chemotherapy use of particular concern for newly diagnosed premenopausal …

Background Chemotherapy-induced premature ovarian insufficiency (POI) impacts fertility
and other aspects of women's health. The OPTION trial tested whether administration of a …

This is a comment on" Randomized trial using gonadotropin-releasing hormone agonist
triptorelin for the preservation of ovarian function during (neo) adjuvant chemotherapy for …

Background Premature ovarian failure and infertility following chemotherapy are major
concerns for premenopausal women with breast cancer. A potential ovarian function …

In the meta-analysis by Elgindy and colleagues, the use of gonadotropinreleasing hormone
(GnRH) analogs during chemotherapy did not show to significantly increase ovarian function …

Background Ovarian failure is a common toxic effect of chemotherapy. Studies of the use of
gonadotropin-releasing hormone (GnRH) agonists to protect ovarian function have shown …

The use of chemotherapy in premenopausal cancer patients may lead to chemotherapy-
induced premature ovarian failure. Pharmacological temporary ovarian suppression …